Correlations between multiple obesity diagnostic criteria and fracture risk as well as cardiovascular diseases in patients with diabetes mellitus - Summary - MDSpire
To analyze the global disease burden of high body mass index (BMI) and evaluate the associations between three obesity diagnostic criteria and waist-to-height ratio (WHtR) with fracture risk and cardiovascular diseases (CVD) in diabetic patients.
Approach:
Data Sources: Data on high BMI burden in China and globally (1990–2021) were sourced from the Global Health Data Exchange (GHDx).
Study Design: A cross-sectional clinical study enrolled 17,949 diabetic participants from a single center in China.
Obesity Diagnosis: Obesity was diagnosed using WHO, EASO, and AOU criteria.
Statistical Analysis: Logistic regression models were employed to analyze associations between WHtR and CVD, high-risk hip fracture (HRHF), and high-risk major osteoporotic fracture (HRMOF), adjusting for multiple covariates.
Key Findings:
From 1990 to 2021, the age-standardized rate of high BMI in China increased by 146.22%, exceeding the global increase of 70.89%.
EASO criteria showed significant associations with CVD.
WHtR was a significant risk factor for CVD and hip fracture across all models.
The highest WHtR tertile was associated with increased risks of CVD (OR = 1.14, 95% CI: 1.04–1.25) and HF (OR = 1.83, 95% CI: 1.41–2.62) compared to the lowest tertile.
Interpretation:
Elevated WHtR was independently associated with higher risks of CVD and HF in the diabetic population.
Limitations:
The study is limited to a single center in China, which may affect generalizability.
Cross-sectional design limits causal inferences.
Conclusion:
The high BMI burden is rising markedly, especially in China. Integrating WHtR into clinical practice could improve risk stratification for obesity-related comorbidities.
These 10 states have paid family or medical leave programs and health, wellness, peer support, or monitoring resources available to physicians or other health professionals.
Investigators compared cardiovascular outcomes with tirzepatide and a placebo proxy in patients with type 2 diabetes and established atherosclerotic cardiovascular disease.
